Drugs / AMO959
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07226986 | Dec 2025 → Jul 2028 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMO959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226986 ↗ |
| Action | Inhibit | “DNA Damage Response inhibitor” NCT07226986 ↗ |